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Evaluating the Utility of CYP2C219 Genetic Testing for P2Y12 Inhibitor
Prescribing Within an Inpatient Setting
Health & Services

Thomas E. Maslo, Pharm.D. and Carolynn Null, Pharm.D.

Background

The American College of Cardiology (ACC), the American Heart
Association (AHA), and the European Society of Cardiology (ESC) favor
ticagrelor or prasugrel over clopidogrel in patients diagnosed with ACS
who receive DAPT post-PCI.1 These guidelines do not recommend for
routine genetic testing. Comparatively, the Clinical Pharmacogenetics
Implementation Consortium provides guidance on tailored P2Y12
inhibitor therapy dependent on CYP2C19 status, with ticagrelor or
prasugrel being favored in poor or intermediate metabolizers.2
Consequently, selection of a P2Y12 inhibitor may be influenced by both
prescribing practices and patient-specific factors.
Approximately 30% of the North American population carry at least one
CYP2C19 allele associated with reduced metabolism of clopidogrel,
potentially increasing their risk for adverse outcomes and treatment
failure.3 Ticagrelor and prasugrel are not impacted by CYP2C19
metabolism, but are associated with increased bleeding risk and cost.
The utilization of CYP2C19 genetic testing could optimize P2Y12
inhibitor prescribing, potentially resulting in improved clinical outcomes
and cost savings. Recent studies have provided increasingly positive
evidence that a genotype-guided strategy for DAPT results in reduced
adverse events.4,5 Additionally, future guideline recommendations may
be impacted by these studies. This retrospective cohort analysis aims to
identify how CYP2C19 genetic testing may impact clinical practice within
an inpatient setting.
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Figure 2. Prescribing Rates Per Index Diagnosis
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Primary
• Evaluate the incidence of optimal P2Y12 inhibitor prescribing in a
retrospective cohort
o

Defined as those projected to have at least one loss of function allele being
prescribed ticagrelor or prasugrel (30%), and those projected without a loss of
function allele being prescribed clopidogrel (70%)

Secondary
• Evaluate readmissions associated with major cardiovascular
adverse events (MACE) at 30 days and 1 year
• Evaluate readmissions associated with stent thrombosis at 30
days and 1 year
• Perform a cost analysis between the study cohort and a
simulated cohort utilizing a genotype-guided strategy at 1 year

Methodology

60%

50.0%

50%

40.0%
81.3%

40%

75.5%

64.8%

62.5%

30%

53.4%
46.6%

30.0%

73.1%

23.8%

22.0%

20.0%

20%

10.0%

10%

1.0%

0.0%

0%

NSTEMI
(N=200)
Clopidogrel

2016
2017
2018
2019
Total
(N=8)
(N=75) (N=196) (N=122) (N=401)
Clopidogrel
Ticagrelor
Prasugrel

0.7%

0.0%
STEMI
(N=58)
Ticagrelor

UA
(N=143)
Prasugrel

Note: Prescribing rates were not found to be significantly different between NSTEMI
vs. UA (p=0.71). However, prescribing rates were found to be significantly different
between NSTEMI vs. STEMI (p=0.00) and UA vs. STEMI (p=0.00)
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Figure 4. Initial Readmission Events Over 1 Year
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Note: Statistically significant differences (p=0.01) were found between “MACE plus
other” rates between the clopidogrel and ticagrelor groups

Figure 5. Cumulative Failure Rates Over Time

Table 1. Event Rates Over 30 Days and 1 Year
Event rate (per 100-patient years) Over 30 Days
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Table 2. Evaluation of Genotype-guided DAPT over 1 year

Prescribing
frequency

Clopidogrel

Ticagrelor

$60

$4,624

0.73

0.26

P2Y12 Inhibitor
(Rx)
Cost of 1 year
supply‡ per
person
Prescribing
frequency

Clopidogrel

Ticagrelor

$60

$4,624

0.73

0.26

N/A

CYP2C19 Test†

Total Cost of Rx
plus Test

$495,924

Total Cost of Rx
plus Test

$684,640

Total Event
Incidence

15.3%

Total Event
Incidence4

6.6%

Total Events

61

Total Events

26

$1,120,997

Total Aggregate
Cost of Events◊

$477,802

$1,616,921

Total Cost of Rx
Plus Test Plus
Events

$1,089,544

CYP2C19

Total Aggregate
Cost of Events◊
Total Cost of Rx
Plus Test Plus
Events

Figure 6. Cost-analysis Among Cohorts
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Limitations of this retrospective cohort study include the potential for
missed events not documented within the electronic medical record and
the inability to control for other confounding factors. There was also
notable attrition within the ticagrelor group, with 45 patients
discontinuing therapy after a median of 37 days. Discontinuation of
ticagrelor was most commonly associated with cost and dyspnea, at
49% and 29%, respectively. However, this high rate of discontinuation
supports the utilization of a genotype-guided strategy in matching
patients with the most optimal agent in regards to tolerability and cost.
Lastly, CYP2C19 status is not the only contributor associated with a
poor response to clopidogrel, and this study did not assess other factors
contributing towards platelet reactivity.

This retrospective cohort study at two large, tertiary medical centers
demonstrated that overall P2Y12 inhibitor prescribing rates compared
favorably to the expected distribution of CYP2C19 phenotypes among
the North American population, with a trend towards increased
prescribing of ticagrelor. However, significantly increased MACE plus
other ischemic events over 1 year in the clopidogrel group demonstrate
that P2Y12 inhibitor prescribing can be optimized utilizing a genotypeguided strategy.

Cost of
CYP2C19
Test - B

$0
$115,818

As event rates were higher within the initial 30 day period post-PCI,
initiating CYP2C19 genetic screening promptly and during inpatient
admission may help minimize early readmission. CYP2C19 genetic
screening may also help guide optimal prescribing practices in
consideration of other factors, such as the tolerability of the medication
regimen. Lastly, a genotype-guided strategy may reduce costs for both
the health system and the patient.

$495,924

Total Cost of Rx

Test†

A simulated analysis was completed utilizing incidence rates associated
with a genotype-guided strategy,4 and also utilizing prescribing
frequencies demonstrated by this study. The rate of MACE and other
ischemic events was reduced by 57% in the simulated cohort. This
reduction equated to savings of $527,377, or $1,325 per person, with
savings attributed to reduced readmissions due to adverse outcomes.

Simulated Cohort (N=398)

$495,924

Total Cost of Rx

Event rates among both groups are more pronounced within the initial
30 days post-index PCI, with 26% of total initial readmissions occurring
during this period. These rates highlight the necessity of early, targeted
P2Y12 inhibitor prescribing. Additionally, individuals receiving clopidogrel
showed a significantly higher incidence of MACE plus other ischemic
events (p=0.01) occurring after 1 year. Cumulative failure rates for the
clopidogrel group were also comparatively higher throughout the entirety
of this period.

MACE
plus other

Clopidogrel
(N=293)

P2Y12 Inhibitor
(Rx)
Cost of 1 year
supply‡ per
person

Prescribing habits showed that ticagrelor is more likely to be prescribed
with an index diagnosis of STEMI, compared to NSTEMI or unstable
angina. Within the past year, the POPular Genetics trial suggests that a
genotype-guided strategy, with 61% of patients receiving clopidogrel,
was non-inferior to those receiving ticagrelor in patients diagnosed with
STEMI and undergoing PCI.5 The genotype-guided arm also
experienced significantly fewer minor bleeding events. Thus, CYP2C19
screening may help support prescriber decision-making in consideration
of the index diagnosis.

Conclusion

Event rate (per 100-patient years) Over 1 Year

P2Y12
Inhibitor

From September 2016 through September 2019, overall P2Y12 inhibitor
prescribing rates compared favorably to the optimal prescribing rates
noted in the primary objective. Ticagrelor or prasugrel were prescribed at
an overall rate of 26.9%, while clopidogrel was prescribed at a rate of
73.1%. Additionally, prescribing of ticagrelor has increased over time,
being possibly influenced by ACC/AHA and ESC guideline updates.

A potential explanation for the increased event rates in the clopidogrel
group is individuals, with one or more loss of function alleles, are being
sub-optimally prescribed clopidogrel. A genotype-guided strategy could
help mitigate these risks by allowing for targeted P2Y12 inhibitor
prescribing, resulting in improved clinical outcomes.
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Study Cohort (N=398)

Study period:
• September 2016 through September 2019
Data collection:
• Electronic health record-based retrospective cohort
Study population:
• Patients >18 years old undergoing PCI with drug-eluting stent
placement
• Patients prescribed DAPT – consisting of clopidogrel,
ticagrelor, or prasugrel – upon discharge
• Patients presenting with acute coronary syndrome
Exclusion criteria:
• Past and/or current diagnosis of cancer
• Pregnancy
• To ensure appropriate length of follow-up, patients were also
excluded if they did not have a documented chart encounter
after 30 days of the index PCI
Outcomes measured:
• MACE, defined as myocardial infarction (MI) or ischemic stroke
(IS)
• Other ischemic events, defined as stent thrombosis (ST) or
unstable angina (UA)

75.5%

60.0%

To evaluate the potential utility of CYP2C19 genetic testing for patients
presenting with ACS and receiving DAPT after undergoing PCI within
two large, tertiary medical centers

Objectives

77.0%

70.0%

Count

In patients presenting with ACS and undergoing percutaneous coronary
intervention (PCI) with stent placement, dual antiplatelet therapy (DAPT)
is routinely prescribed for a minimum of 12 months post-PCI1. DAPT
consists of a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) plus
aspirin.

Results

Count

The emergence of pharmacogenomics offers the opportunity to practice
precision medicine across healthcare, including within patients
presenting with acute coronary syndrome (ACS).

Discussion

$115,818

‡= RED BOOK Online. Micromedex Healthcare Series [database online]6
†=Centers for Medicare and Medicaid Services (CMS) 2020 Clinical Laboratory Fee Schedule
◊=CMS Inpatient Charge Data FY 2017
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